Back to News
Market Impact: 0.35
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
Source: benzinga.com
Healthcare & BiotechRegulation & LegislationCorporate Guidance & Outlook
The FDA extended by three months its review of Exelixis's NDA for zanzalintinib combined with atezolizumab in metastatic colorectal cancer. The delay postpones a potential approval decision and near-term commercialization catalyst for Exelixis, creating additional regulatory uncertainty for the drug program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
EXEL-0.45
More News
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Bucher Industries sees lower 2026 sales, margins as glass, farm units slump
- USTR Greer tells EU that loan to Airbus threatens trade truce on aircraft financing
- EQT becomes the nation’s leading natural gas ‘juggernaut’ with a $13B deal as data center, export demand surges
- Bank of England reviews Revolut’s product approval controls - report